Small-molecule NGF/pro-NGF inhibitors are also under pre-clinical investigation for their ability to disrupt NGF/proNGF binding to TrkA and p75NTR in the context of osteoarthritis [144]. The gene discussed is NGF; the disease is osteoarthritis.